期刊
JOURNAL OF DERMATOLOGICAL TREATMENT
卷 34, 期 1, 页码 -出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/09546634.2023.2177096
关键词
Atopic dermatitis; nemolizumab; pruritus; quality of life
类别
The background data from the Japanese phase 3 study showed that nemolizumab in combination with topical treatments can reduce pruritus in atopic dermatitis. This post-hoc analysis found that improvements in pruritus were associated with improvements in eczema symptoms, sleep quality, and daily life.
Background Data from the Japanese phase 3 Nemolizumab-JP01 study (JapicCTI-173740) found that nemolizumab in combination with topical treatments reduced pruritus associated with atopic dermatitis inadequately controlled with current therapies. Methods This post-hoc analysis examined associations between improvements in pruritus (visual analog scale [VAS]) and eczema (Eczema Area and Severity Index [EASI]), and achievement of other clinically relevant endpoints including the Insomnia Severity Index (ISI), Dermatology Life Quality Index (DLQI), and Patient-Oriented Eczema Measure (POEM). Results Pruritus VAS responders (>= 50% improvement from baseline to week 16) showed greater improvements from baseline in these additional endpoints as early as week 1, compared with non-responders. Responders also had EASI improvement, and more than 80% achieved an ISI score <= 7, or had improvement in the DLQI or POEM. The percent change from baseline in VAS and EASI scores at week 16 was in favor of nemolizumab in all subgroups based on baseline characteristics. No specific factor affecting treatment response to nemolizumab was identified. Conclusions In this post-hoc analysis, nemolizumab-treated patients who had greater pruritus reductions also showed improvements in other eczema symptoms; pruritus alleviation appeared to be responsible for the improvements in eczema, sleep and daily life.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据